Search

Displaying results 7981 - 7990 of 10000 in total
  1. Drug

    Tabalumab

    go.drugbank.com/drugs/DB11657
    Investigational

    Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.

    Categories: Amino Acids, Peptides, and Proteins
  2. Drug

    Buthionine sulfoximine

    go.drugbank.com/drugs/DB12870
    Investigational

    Buthionine sulfoximine has been used in trials studying the treatment of Neuroblastoma and Melanoma (Skin).

    Categories: Amino Acids, Peptides, and Proteins
  3. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).

  4. Drug

    Indusatumab vedotin

    go.drugbank.com/drugs/DB12413
    Investigational

    Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and

    Categories: Amino Acids, Peptides, and Proteins
  5. Drug

    Ligandrol

    go.drugbank.com/drugs/DB13934
    Investigational

    Ligandrol is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis.

  6. Drug

    Teverelix

    go.drugbank.com/drugs/DB05624
    Investigational

    A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.

    Categories: Amino Acids, Peptides, and Proteins, Hormones, Hormone Substitutes, and Hormone Antagonists
  7. Drug

    Acotiamide

    go.drugbank.com/drugs/DB12482
    Investigational

    Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.

    Categories: Alimentary Tract and Metabolism
  8. Drug

    V591

    go.drugbank.com/drugs/DB16438
    Investigational

    Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593].

  9. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  10. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.